Company Overview
CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company dedicated to the three-dimensional bioprinting of tissues and organs, alongside medical aesthetics initiatives across the United States, Canada, Israel, Europe, and international markets. The firm's product portfolio relies on recombinant human collagen technology, positioning the entity within the broader Healthcare sector and the specialized Biotechnology industry, which typically involves high research and development expenditures before commercialization. This biotechnology entity maintains a market capitalization of $7.99M and generates annual revenue of $2.48M while employing a workforce of 57 individuals. The combination of a sub-$10M market cap and revenue under $3M indicates that CollPlant is currently a micro-cap entity operating with limited financial scale relative to established large-cap peers, suggesting a stage of early commercialization or significant capital deployment for future product rollout.
Financial Health
The company reported revenue of $2.48M over the trailing twelve months, yet recorded a net income of $-12,160,000 and an EBITDA of $-11,369,000, revealing a substantial gap where operating costs and expenses significantly exceeded revenue generation. This disparity highlights a cost structure driven by heavy investment in research, development, and potentially manufacturing scale-up costs that have not yet been offset by profitable operations. Free cash flow stands at $-5,760,875, which indicates that the company is burning cash at a rate that requires continuous capital infusion from cash reserves or external financing to sustain operations. The balance sheet shows available cash of $8.55M against total debt of $2.94M, providing a liquidity buffer, although the debt-to-equity ratio of 31.60 suggests the company utilizes debt financing relative to its equity base. A current ratio of 3.66 demonstrates strong short-term liquidity, indicating that the company holds sufficient current assets to cover its current liabilities more than three times over. Return on Equity is -92.7% and Return on Assets is -42.1%, metrics that reveal management has not yet generated positive returns on the capital invested in the business, a common characteristic for biotechnology firms in pre-profitability stages.
Valuation Assessment
The company presents a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at -1.60, a valuation metric that typically implies negative earnings expectations or a mathematical anomaly common in loss-making biotechnology companies. The price-to-book ratio is 0.86, indicating that the market values the company at approximately 14% below its net asset value, which may reflect skepticism regarding the recoverability of its intangible assets or the realization of its bioprinting technology. Alternative valuation metrics show a price-to-sales ratio of 3.23 and an EV/EBITDA of -0.25, suggesting that investors are pricing the firm primarily on its sales potential and cash position rather than current earnings power or discounted cash flow multiples. The stock has exhibited significant price volatility, with a 52-week high of $4.98 and a 52-week low of $0.49, meaning the current market price sits at 86.1% of the 52-week high and 163.3% of the 52-week low. With a beta of 0.95, the stock's price movements correlate closely with the broader market, implying that CollPlant does not exhibit extreme sensitivity to market swings compared to high-beta biotechnology stocks.
Growth & Income
CollPlant Biotechnologies Ltd. has reported a revenue growth rate of 1825.0% year-over-year, while earnings growth is listed as N/A, indicating that revenue expansion is occurring in the absence of profitability. The divergence between rapid revenue growth and the lack of earnings growth implies that the company is prioritizing market penetration and sales volume over immediate profit margins, a strategy typical for capital-intensive life sciences startups. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available cash flow is retained within the business to fund ongoing research, development, and operational scaling rather than being distributed to shareholders. The overall growth and income profile is characterized by explosive top-line expansion supported by a robust cash balance, but the absence of earnings growth and dividend income reflects the transitional nature of the business as it navigates the path to commercial viability.